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Dear editor
The increasing prevalence of obesity can be considered an alarming issue throughout 
the world.1 In only 4 years, for example, the People’s Republic of China has experi-
enced an increase in the overweight population from 29.1% to 34.4%.2 Therefore, we 
would like to congratulate Xu et al3 for conducting an elegant study on a less explored 
topic: the accumulation of visceral fat in kidney disease. The rise in obesity may 
result, at least in part, from changes in lifestyle, currently characterized by sedentary, 
poor eating, and sleep habits. The reduction in sleep duration is known to predispose 
individuals to obesity by increasing the white adipose tissue deposits such as visceral 
fat.4,5 Of note, obesity and visceral fat accumulation are etiopathological factors for 
both chronic kidney disease (CKD) and sleep disorders.6,7
A sleep disorder that is closely related to obesity and CKD is obstructive sleep apnea 
(OSA).8,9 OSA is characterized by partial or complete obstruction of the pharyngeal 
airway during sleep, leading to repeated breathing pauses, oxygen desaturation, and 
arousals.10 It is known that 70% of patients with OSA are overweight and have higher 
intra-abdominal visceral fat accumulation11 and 40% of obese people have OSA.7 In 
CKD, the situation may be worse as OSA affects up to 94% of these patients.12 In obese 
people, the obstruction of pharyngeal airway becomes more frequent during sleep due 
to the local accumulation of fat in the neck region, which anatomically blocks the 
airways in the lying position.9 In CKD, this occurs also due to the accumulation of 
body liquids and its shift to the neck region, which compresses the pharynx, leading to 
apneas.13 It is important to consider that OSA and visceral fat accumulation represent 
risk factors for the development and progression of CKD.14
In this context, we believe that OSA screening in individuals with visceral fat 
accumulation can be very relevant to predict the decline in glomerular filtration rate. 
As indicated by the authors, visceral fat accumulation acts as a predictive factor for 
CKD; thus, evaluation of OSA may be relevant since it has been considered as a new 
risk factor for CKD. There are some questionnaires that evaluate sleep-disordered 
breathing risk subjectively, and, in addition, there is the polysomnography, the gold 
standard examination for diagnosis of OSA. In conclusion, we believe that implement-
ing OSA screening in clinical practice when dealing with obesity and CKD is very 
important and may help future research in acquiring evidence for complementary 
therapeutic treatments based on sleep, since OSA can act as a possible aggravating 
factor in CKD.
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